Michael O'Dwyer

Assoc. Professor of Medicine MB, BCH, BAO (Hons) MRCPI, MRCPATH

Contact Details

Assoc. Professor of Medicine
Dept. of Medicine/Haematology
NUI
Galway

T: 87-2349
E: michael.odwyer@nuigalway.ie
 
researcher

Biography

Peer Reviewed Journals

  Year Publication
(2011) 'SE. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia'
McCarron SL, Kelly J, Coen N, McCabe S, Fay M, O'Dwyer M, Hayden PJ, Langabeer (2011) 'SE. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia'. Leuk Lymphoma, 52 (5):919-921 [Details]
(2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic'
Van Dijk M, Murphy E, Morrell R, Knapper S, O'Dwyer M, Samali A and Szegezdi E. (2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic'. Differentiation to TRAIL Mediated Apoptosis Cancers, 3 (1):1329-1350 [DOI] [Details]
(2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'
Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K,Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS (2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 (18):3796-3800 [DOI] [Details]
(2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'
Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, (2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'. Review, 191 (1):W91-W103 [DOI] [Details]
(2010) 'Clofarabine in the treatment of poor risk acute myeloid leukaemia'
Krawczyk, J,Ansar, N,Swords, R,Murphy, T,MacDonagh, B,Meenaghan, T,Hayden, P,Hayad, A,Murray, M,O'Dwyer, M (2010) 'Clofarabine in the treatment of poor risk acute myeloid leukaemia'. Hematological Oncology, 28 :118-123 [DOI] [Details]
(2010) 'Cdc7 kinase - a new target for drug development'
Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F (2010) 'Cdc7 kinase - a new target for drug development'. European Journal Of Cancer, 46 (1):33-40 [DOI] [Details]
(2010) 'administration of bortezomib: making a difference to myeloma patients' lives. Eur'
Meenaghan T, O'Dwyer M, Hayden P, Hayat A, Murray M, Dowling M. Home (2010) 'administration of bortezomib: making a difference to myeloma patients' lives. Eur'. J Oncol Nurs, 14 (2):134-136 [Details]
(2009) 'Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era'
O'Dwyer, M,Atallah, E (2009) 'Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era'. Seminars In Hematology, 46 :16-21 [DOI] [Details]

Abstract

  Year Publication
(2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.
O'Dwyer, MC,Kent, E,Parker, M,Swords, RT,Giles, F,le Coutre, P,Padmanabhan, S,Moulton, B,McMullin, MF,Langabeer, S,Egan, K,Conneally, E (2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. Abstract [Details]

Downloads